Literature DB >> 11396095

Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts.

G S Panayi1, V M Corrigall, C Pitzalis.   

Abstract

The evidence coming from the different experimental approaches reviewed in this article strongly supports the hypothesis that RA is T-cell driven at all stages of the disease. Although the effector phases responsible for the events that lead to joint destruction involve several different cell types, cytokines, and other mediators, T cells still direct operations behind the scenes. Direct experimental proof of this proposition in patients is still lacking, but the development of nondepleting modulating CD4 monoclonal antibodies may provide new tools to test this hypothesis. In this respect, it is encouraging that using one such reagent, we have recently shown that not only did the activity of the disease improve but, more importantly, the inflammatory indices and production of non-T-cell cytokines were reduced. This is not to dissimilar from the results of experiments described in animals, where by blocking synovial T cells, the production of IL-1 beta and TNF alpha could be decreased by more than 90%. From this perspective, it may be predicted that by modulating T cells in the joint, it is possible to achieve our ultimate goal of permanently switching off the disease.

Entities:  

Mesh:

Year:  2001        PMID: 11396095     DOI: 10.1016/s0889-857x(05)70204-0

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  25 in total

1.  Streptococcal cell wall induced arthritis: leukocyte activation in extra-articular lymphoid tissue.

Authors:  Donald Kimpel; Tim Dayton; Krishnaswamy Kannan; Robert E Wolf
Journal:  Inflammation       Date:  2003-04       Impact factor: 4.092

Review 2.  Inflammation and rheumatoid arthritis.

Authors:  Amit Kumar Shrivastava; Aparna Pandey
Journal:  J Physiol Biochem       Date:  2012-10-31       Impact factor: 4.158

3.  Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.

Authors:  Lazaro E Aira; Patricia Hernández; Dinorah Prada; Araceli Chico; Jorge A Gómez; Zuyén González; Karla Fuentes; Carmen Viada; Zaima Mazorra
Journal:  MAbs       Date:  2015-10-15       Impact factor: 5.857

4.  MSC Therapeutics in Chronic Inflammation.

Authors:  Alex Sargent; Robert H Miller
Journal:  Curr Stem Cell Rep       Date:  2016-03-29

5.  Tumour necrosis factor-alpha and leukotriene B(4) mediate the neutrophil migration in immune inflammation.

Authors:  C Canetti; J S Silva; S H Ferreira; F Q Cunha
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients.

Authors:  Christiane Aguiar Nobre; Maria Roseli Monteiro Callado; José Rubens Costa Lima; Kirla Wagner Poti Gomes; Germana Vasconcelos Mesquita Martiniano; Walber Pinto Vieira
Journal:  Rheumatol Int       Date:  2011-08-07       Impact factor: 2.631

7.  Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.

Authors:  Xiaolei Tang; David E Yocum; David Dejonghe; Kathryn Nordensson; Douglas F Lake; John Richard
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

8.  Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy.

Authors:  Ilhan Sezer; Hilal Kocabas; Meltem Alkan Melikoglu; Mehmet Arman
Journal:  Clin Rheumatol       Date:  2008-08-08       Impact factor: 2.980

Review 9.  Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities.

Authors:  Petros Efthimiou; Manil Kukar
Journal:  Rheumatol Int       Date:  2009-10-30       Impact factor: 2.631

10.  MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis.

Authors:  Jianya Huan; Laurie J Kaler; Jeffery L Mooney; Sandhya Subramanian; Corwyn Hopke; Arthur A Vandenbark; Edward F Rosloniec; Gregory G Burrows; Halina Offner
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.